X0306 4 2016-03-15 0 0001510580 Kite Pharma, Inc. KITE 0001609643 Roberts Margo R C/O KITE PHARMA, INC. 2225 COLORADO AVENUE SANTA MONICA CA 90404 0 1 0 0 Chief Scientific Officer Common Stock 2016-03-15 4 M 0 7500 0.70 A 18155 D Common Stock 2016-03-15 4 M 0 1006 17.00 A 19161 D Common Stock 2016-03-15 4 S 0 7815 45.09 D 11346 D Common Stock 2016-03-15 4 S 0 436 46.34 D 10910 D Common Stock 2016-03-15 4 S 0 255 47.78 D 10655 D Employee Stock Option (Right to Buy) 0.70 2016-03-15 4 M 0 7500 0.00 D 2023-10-07 Common Stock 7500 56250 D Employee Stock Option (Right to Buy) 17.00 2016-03-15 4 M 0 1006 0.00 D 2024-06-18 Common Stock 1006 30575 D Includes 1,557 shares acquired under the 2014 Employee Stock Purchase Plan on February 19, 2016. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.05 to $46.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.27 to $48.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the 150,000 shares subject to the stock option vested and became exercisable on August 19, 2014, and the remaining shares subject to the stock option vest and become exercisable in 36 monthly installments as of the last calendar day of each month following the initial vesting date. 25% of the 50,000 shares subject to the stock option vested and became exercisable on June 19, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 monthly installments as of the last calendar day of each month following the initial vesting date. /s/ David M. Tanen, Attorney-in-Fact 2016-03-16